Genome Editing Technologies: Defining a Path to Clinic: Genomic Editing: Establishing Preclinical Toxicology Standards, Bethesda, Maryland 10 June 2014.

Recently developed genomic editing technologies have the potential to be powerful tools for gene therapy because of their ability to inactivate genes, correct mutated sequences, or insert intact genes. While the genomic editing field is advancing at an exceptionally rapid pace, there remain key issues regarding development of appropriate preclinical assays to evaluate off-target effects and establish safety. In order to begin a dialogue on these issues, the National Institutes of Health (NIH) Office of Science Policy, in collaboration with several NIH-funded investigators and the NIH Recombinant DNA Advisory Committee, organized a workshop on 10 June 2014, in Bethesda, Maryland, to provide a forum to educate the scientific and oversight communities and the public on different genome editing technologies, clinical experiences to date, and the preclinical assays being developed to examine the precision of these tools and their suitability for clinical application.

[1]  Morgan L. Maeder,et al.  Comparison of zinc finger nucleases for use in gene targeting in mammalian cells. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Gabriela Plesa,et al.  Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. , 2013, Human gene therapy.

[3]  J. Keith Joung,et al.  High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.

[4]  John T. Gray,et al.  Mouse Transplant Models for Evaluating the Oncogenic Risk of a Self-Inactivating XSCID Lentiviral Vector , 2013, PloS one.

[5]  Gang Bao,et al.  Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing. , 2014, Cell reports.

[6]  David Mittelman,et al.  Lentiviral and targeted cellular barcoding reveals ongoing clonal dynamics of cell lines in vitro and in vivo , 2014, Genome Biology.

[7]  Jeremy M. Stark,et al.  Extensive Loss of Heterozygosity Is Suppressed during Homologous Repair of Chromosomal Breaks , 2003, Molecular and Cellular Biology.

[8]  Michel Sadelain,et al.  Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells , 2011, Nature Biotechnology.

[9]  David R. Liu,et al.  Revealing Off-Target Cleavage Specificities of Zinc Finger Nucleases by In Vitro Selection , 2011, Nature Methods.

[10]  David Baker,et al.  megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering , 2013, Nucleic acids research.

[11]  Dana Carroll,et al.  Targeted genome engineering techniques in Drosophila. , 2014, Methods.

[12]  M. Sadofsky,et al.  The RAG proteins in V(D)J recombination: more than just a nuclease. , 2001, Nucleic acids research.

[13]  Martin J. Aryee,et al.  GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases , 2014, Nature Biotechnology.

[14]  Y. Doyon,et al.  Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme , 2012, Genome research.

[15]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[16]  Jonathan E Foley,et al.  Engineering customized TALE nucleases (TALENs) and TALE transcription factors by fast ligation-based automatable solid-phase high-throughput (FLASH) assembly. , 2013, Current protocols in molecular biology.

[17]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[18]  Kerstin Cornils,et al.  Retroviral Insertional Mutagenesis Can Contribute to Immortalization of Mature T Lymphocytes , 2011, Molecular medicine.

[19]  Dana Carroll,et al.  Genome engineering with targetable nucleases. , 2014, Annual review of biochemistry.

[20]  A. Bogdanove,et al.  TAL Effectors: Customizable Proteins for DNA Targeting , 2011, Science.

[21]  Hung Fan,et al.  Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  Hojun Li,et al.  In vivo genome editing restores hemostasis in a mouse model of hemophilia , 2011, Nature.

[23]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[24]  Ken W. Y. Cho,et al.  Targeted genome editing in human cells using CRISPR/Cas nucleases and truncated guide RNAs. , 2014, Methods in enzymology.

[25]  Jeffry D. Sander,et al.  CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.

[26]  David A. Scott,et al.  Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity , 2013, Cell.

[27]  David R. Liu,et al.  Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification , 2014, Nature Biotechnology.

[28]  Richard L. Frock,et al.  Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases , 2014, Nature Biotechnology.

[29]  J Keith Joung,et al.  Genome Editing: A Tool For Research and Therapy: Towards a functional understanding of variants for molecular diagnostics using genome editing , 2014, Nature Medicine.

[30]  B. Meyer,et al.  Dramatic Enhancement of Genome Editing by CRISPR/Cas9 Through Improved Guide RNA Design , 2015, Genetics.

[31]  Claudio Mussolino,et al.  TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity , 2014, Nucleic acids research.

[32]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[33]  M. Stratton,et al.  RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia , 2014, Nature Genetics.

[34]  C. Barbas,et al.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.

[35]  Michel Sadelain,et al.  Safe harbours for the integration of new DNA in the human genome , 2011, Nature Reviews Cancer.

[36]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[37]  Mark Gerstein,et al.  Personal genome sequencing: current approaches and challenges. , 2010, Genes & development.

[38]  Daniel F Voytas,et al.  Efficient design and assembly of custom TALENs using the Golden Gate platform. , 2015, Methods in molecular biology.

[39]  Rob Pieters,et al.  PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events. , 2014, Blood.

[40]  P. Duchateau,et al.  Meganucleases and Other Tools for Targeted Genome Engineering: Perspectives and Challenges for Gene Therapy , 2011, Current gene therapy.

[41]  Carl O. Pabo,et al.  A General Strategy for Selecting High-Affinity Zinc Finger Proteins for Diverse DNA Target Sites , 1997, Science.

[42]  Toni Cathomen,et al.  Highly Efficient Zinc-Finger Nuclease-Mediated Disruption of an eGFP Transgene in Keratinocyte Stem Cells without Impairment of Stem Cell Properties , 2011, Stem Cell Reviews and Reports.

[43]  Jac A. Nickoloff,et al.  Gene Conversion Tracts from Double-Strand Break Repair in Mammalian Cells , 1998, Molecular and Cellular Biology.

[44]  Gang Bao,et al.  CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences , 2014, Nucleic acids research.